Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 972,915 shares of the company’s stock after selling 38,775 shares during the quarter. Truist Financial Corp owned 0.08% of Teva Pharmaceutical Industries worth $19,653,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Cromwell Holdings LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the period. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries in the second quarter worth about $41,000. JTC Employer Solutions Trustee Ltd bought a new position in Teva Pharmaceutical Industries in the third quarter worth about $65,000. MAI Capital Management boosted its stake in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after acquiring an additional 697 shares during the period. Finally, CWM LLC grew its holdings in shares of Teva Pharmaceutical Industries by 18.1% during the second quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $34.08 on Friday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $34.11. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The stock has a market cap of $39.09 billion, a PE ratio of 28.40, a price-to-earnings-growth ratio of 1.88 and a beta of 0.66. The company’s 50-day moving average price is $30.49 and its two-hundred day moving average price is $23.15.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY?2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third?party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

Wall Street Analysts Forecast Growth

TEVA has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Jefferies Financial Group lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 622,060 shares of company stock worth $17,076,965 in the last 90 days. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.